We found that the protective effect of the anti-inflammation drug rosuvastatin (RSV) was associated with its ability to inhibit the activation of NLRP3 inflammasome via TXNIP and suppress the phosphorylation of MAPK signal pathways in DCM (Luo et al., 2014a). Here, NLRP3 is linked to familial dilated cardiomyopathy.